Although n-3 (v-3) polyunsaturated fatty acids (PUFAs) are considered anti-inflammatory components, the role of dietary n-6 PUFAs in inflammation remains controversial. Some mechanistic evidence suggests vitamin E as a potential effect modifier in the relationship between PUFAs and inflammation. Our objectives were to evaluate the long-term associations between dietary intakes of PUFAs and elevated plasma C-reactive protein (CRP) and to investigate potential effect modification by vitamin E. Individuals in the placebo group of the SU.VI.MAX trial who had available CRP measurements in 2007-2009 were included in the study (n = 843). Dietary intakes of n-3 PUFAs, n-6 PUFAs, and vitamin E were assessed in 1994-1996 with at least 6 dietary records. The logistic regression OR for elevated CRP (>3 mg/L) and 95% CI were estimated for individual PUFAs and for total n-3 and n-6 PUFA intakes. Models were adjusted for sociodemographical, lifestyle, anthropometric, and dietary variables. Interactions with vitamin E intakes were also assessed.
Introduction
Low-grade inflammation has been recognized as an underlying process for several chronic diseases, including cancer and cardiovascular diseases (1) (2) (3) . Identification of modifiable risk factors for low-grade inflammation could therefore contribute to understanding and preventing the early stages of chronic diseases.
PUFAs are of utmost interest, because they are precursors for several pro-or anti-inflammatory mediators, including eicosanoids (4) (5) (6) . The main substrate for eicosanoid production is arachidonic acid (AA 12 ; 20:4n-6), but n-3 PUFAs have been identified as alternate sources of production for eicosanoids with lesser inflammatory power (6) . They are also precursors for mediators involved in the resolution of inflammation, protectins and resolvins (7) .
Several studies have investigated relationships between n-3 PUFAs and inflammation, suggesting a protective effect against low-grade inflammation (8) (9) (10) . As to n-6 PUFAs, however, results are controversial. If mechanistic pathways indicate that they are pro-inflammatory factors, results from human observational studies are more equivocal, especially regarding linoleic acid (LA; 18:2n-6) (11, 12) .
Moreover, interaction between PUFAs and vitamin E needs to be further investigated. Vitamin E is a potent antioxidant, with anti-inflammatory properties in experimental studies (13) . Mechanistic hypotheses would suggest vitamin E and n-3 PUFAs have synergistic anti-inflammatory effects (14) . However, animal models have shown that vitamin E and n-3 PUFAs have antagonistic effects, in particular in cancer (15, 16) . Human studies investigating the interaction between n-3 PUFAs and vitamin E intakes in inflammation are therefore of importance. To our knowledge, no epidemiologic study has investigated the potential effect modification by vitamin E in the relationship between PUFAs and inflammatory processes.
Our objectives were therefore to 1) assess long-term relationships between dietary n-3 and n-6 PUFA intakes and elevated plasma status of C-reactive protein (CRP) measured 12 y later and 2) investigate potential effect modifications by vitamin E intakes in a sample of participants from the French SU.VI.MAX study.
Participants and Methods
Study population. The study population was selected from participants in the SU.VI.MAX study. Individuals not taking any supplements were included in 1994-1995 in a randomized, double-blind, placebo-controlled primary prevention trial designed to evaluate the effect of a planned 8-y supplementation in antioxidant vitamins and minerals at nutritional doses on the incidence of cardiovascular disease and cancer (17) . In 2007-2009, individuals were offered to enroll in an additional follow-up study, the SU.VI.MAX2 study (18) .
Both the SU.VI.MAX and the SU.VI.MAX2 studies were approved by the Ethics Committee for Studies with Human Subjects of ParisCochin Hospital (706 and 2364, respectively) and the Comité National Informatique et Liberté (334641 and 907094, respectively). All individuals gave written informed consent to participate in the study. Individuals having had CRP measurements and with CRP values <10 mg/L (19) were included in the present study. Individuals having <6 dietary records in 1994-1996 and individuals having missing data on covariates were excluded from the analyses.
Because vitamin E was included in the supplements used in the trial phase of the SU.VI.MAX study, and because we hypothesized an effect modification by vitamin E intakes, we conducted our analyses only in individuals in the placebo group of the initial SU.VI.MAX trial.
Dietary data assessment. Dietary assessment was carried out through repeated 24-h records, as described previously (17) . Individual n-3 PUFAs [a-linolenic acid (ALA; 18:3n-3), EPA (20:5n-3), docosapentaenoic acid (DPA; 22:5n-3), and DHA (22:6n-3)] n-6 PUFAs (LA and AA), long-chain n-3 PUFAs (EPA+DPA+DHA), total n-3 and n-6 PUFAs, and total intake ratio of n-3 to n-6 PUFAs were computed.
All nutrient intakes were modeled as residuals to take into account energy intakes (20) . A simplified ''prudent'' dietary pattern was constructed (21) based on the prudent dietary pattern described in Kesse-Guyot et al. (22) to account for potential confusion as a result of a more general healthy dietary behavior.
Inflammation measurement. Blood samples were drawn from participants in the SU.VI.MAX2 study, immediately centrifuged, and frozen at 280°C and stored. Plasma CRP concentrations were measured using an immunoturbidimetric assay, with a detection limit of 1 mg/L. Intra-assay and interassay coefficients of variations were 0.61% and 2.87% respectively. Individuals with CRP values >3 mg/L were considered to have elevated CRP (19) .
Covariates. Educational level (primary, secondary, University), physical activity (irregular, <1 h equivalent walking/d, $1 h equivalent walking/ d), and smoking status (never smoked, former smoker, current smoker) data were obtained through self-administered questionnaires at baseline.
Anthropometric measurements were taken during a clinical examination year 1 after inclusion in the SU.VI.MAX study and during the clinical examination for the SU.VI.MAX2 study. Weight was measured in individuals in light clothing and with no shoes to the nearest 0.1 kg, and height was measured to the nearest centimeter with a wall-mounted stadiometer in the same conditions.
Baseline serum cholesterol and glucose concentrations were measured from blood collected after a 12-h fast measured by an enzymatic method using a Technicon flow analysis device (Technicon DAX-24; Bayer Diagnostic).
Statistics. BMI was calculated as weight (in kilograms) divided by square of height (in meters). Dietary n-3 and n-6 PUFA intakes were divided into tertiles. Characteristics of individuals according to plasma CRP status were explored using chi-square tests for categorical variables (presented as number and percentage of individuals with a particular characteristic) and t test for continuous variables (presented as mean 6 SD). OR and 95% CI of having elevated plasma CRP concentrations according to tertiles of individual PUFAs, long-chain n-3 PUFAs, total n-3 and n-6 PUFAs, and total intake ratio of n-3 to n-6 PUFAs were computed using logistic regression. Models were first crude, then adjusted on sex, baseline age, educational level, smoking status, physical activity, energy intake, alcohol intake, number of dietary records available, baseline BMI, difference between baseline and follow-up BMI, and prudent dietary pattern.
Interactions between PUFAs and vitamin E were tested by adding a cross-term between tertiles of PUFAs and tertiles of vitamin E intakes (coded as ordinal variables), and the analyses were repeated by stratifying on vitamin E tertiles (adjusted model only).
In sensitivity analyses, main analyses were repeated in a subset of individuals for whom baseline plasma CRP concentrations had been measured for an ancillary protocol, after exclusion of individuals with elevated baseline plasma CRP concentrations (n = 170). 
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All analyses were performed using SAS software (version 9.3; SAS Institute). Statistical significance was considered for P < 0.05.
Results
In all, 843 individuals corresponded to our criteria and were included in the present analysis (Fig. 1) . Individuals with elevated plasma CRP concentrations were more likely older, with a higher baseline BMI and a higher BMI increase between baseline and follow-up measurements (all P < 0.01) ( Table 1) .
Inverse associations were observed between elevated plasma CRP concentrations and total n-3 PUFA intakes (ALA+EPA+ DPA+DHA, P-trend = 0.01) and long-chain n-3 PUFA intakes (EPA+DPA+DHA, P-trend = 0.05), mainly driven by associations with DPA intakes (P-trend = 0.01) ( Table 2) . Inverse associations were also observed for total n-6 PUFA intakes (LA+AA, P-trend = 0.002), mainly driven by an inverse association with LA intakes (P-trend = 0.004) ( Table 2 ). In sensitivity analyses with individuals having normal baseline plasma CRP concentrations, inverse associations with long-chain n-3 PUFA intakes remained significant (P-trend 5 0.02). Other associations were maintained in the same direction but were no longer significant (data not shown). These results suggested that our main results reflected at least partial longitudinal associations.
P-interaction terms for vitamin E ranged between 0.12 (for DPA) and 0.90 (for DHA). Stratification on tertiles of vitamin E showed that inverse associations with DPA intakes and longchain n-3 PUFA intakes were substantial only in the lowest tertile of vitamin E intake (P-trend across tertiles of PUFA intakes = 0.007 and = 0.043, respectively) ( Table 3) . OR for associations between LA intakes and total n-6 PUFA intakes and plasma CRP level were not computable in the highest tertile of vitamin E intake because of the colinearity between LA and vitamin E intakes.
Discussion
Our results strengthen the contention of an inverse association between dietary n-3 PUFA intakes and inflammation and show that n-6 PUFA intakes in general and LA intakes in particular display the same beneficial pattern as n-3 PUFA intakes. Vitamin E proved to be an effect modifier of DPA and long-chain n-3 PUFAs, for which inverse associations were observed only in individuals with the lowest vitamin E intakes. Some cross-sectional studies have investigated the associations between n-3 PUFA intakes (mainly EPA and DHA) and biomarkers of inflammation and demonstrated an inverse association (8, 9, 23, 24) . Our study extended these results to long-term associations. Moreover, we were able to investigate DPA dietary intakes, which were not taken into account in these studies. Effect of dietary PUFAs is thought to be determined by their circulating concentrations. However, circulating levels of DPA do not correlate well with dietary consumption, but to EPA levels, suggesting that circulating DPA is derived from transformation of circulating EPA rather than directly from dietary sources (25) . This circumstance could explain in part why most studies focus on EPA and DHA. Our results, however, show that dietary DPA should also be considered.
The effect of n-6 PUFAs in inflammation is still debated (11, 26, 27) . AA is the major precursor for pro-inflammatory eicosanoid production, and because LA can serve as a precursor for AA, it is supposed to have similar effects (6) . However, recent research has uncovered possible AA and LA anti-inflammatory properties, because they are also precursors to a range of mediators involved in inflammation resolution (28) .
Human studies investigating the impact of AA and LA on inflammation have given mixed results: observational crosssectional studies have given inconsistent results (23, 24) ; supplementation of healthy individuals with AA increased the production of certain eicosanoids, but it didnÕt alter other inflammatory biomarkers (CRP, IL-6, and TNF-a) (29, 30) ; and supplementation trials with dietary LA in healthy individuals showed neither proor anti-inflammatory effects (12) . Our results suggested a potential anti-rather than pro-inflammatory effect of dietary LA.
Moreover, our results showed similar effect sizes for n-3 and n-6 PUFA intakes, consistent with results by Poudel-Tandukar et al. (24) This finding argues for equal balance between n-3 and n-6 PUFA intakes in preventing inflammation. However, our results need to be replicated for confirmation.
Vitamin E is a potent antioxidant interrupting lipid peroxidation that has been suggested to have antagonistic effects to PUFAs, in particular in carcinogenesis (31) . n-3 PUFAs are able to auto-oxidize; therefore, their incorporation induced lipid peroxidation and apoptosis in vitro and in animal models of cancer (16, 32, 33) . Even so, n-3 PUFAs lead to tumor growth suppression. Adding vitamin E to n-3 PUFAs abolished this effect (16, 32, 33) , suggesting that n-3 PUFA-induced lipid peroxidation would not be toxic per se but rather act as a tumor cell growth and apoptosis regulator (34) .
In vivo human studies have not been able yet to corroborate such hypotheses. In Thièbaut et al. (35) , no statistically significant interaction was observed between n-3 PUFA intakes and vitamin E in the incidence of cancer. In a 6-week double-blind trial with n-3 PUFA or vitamin E alone or in combination, increased lipid peroxidation was not suppressed by vitamin E supplementation (36) .
Our results corroborated the hypothesis of an interaction between n-3 PUFA intakes and vitamin E intakes on inflammatory biomarkers. Substantial inverse associations of PUFA intakes were observed for individuals with the lowest intakes of vitamin E. The lack of statistical significance observed in our study could be the result of both a lack of power, because of our limited sample size, and the limited power of statistical interaction tests. We were not able to obtain statistically stable results for LA intakes when stratifying on vitamin E intakes, because of colinearity between the 2 variables. This colinearity can be explained by the fact that LA and vitamin E share the same food sources, because they are found mostly in vegetable oils (Supplemental Table 1 ).
Our study was subject to some limitations. First, plasma CRP concentration was measured with a detection limit as high as 1 mg/L. However, this detection limit still allowed us to classify individuals according to cardiovascular risk (19) . Second, plasma CRP concentration was not measured at baseline except for a small sample of individuals. Our results could therefore reflect preexisting associations between PUFA intakes and plasma CRP concentrations. However, the sensitivity analysis yielded similar results, showing that the observed associations reflect at least partial longitudinal associations. Finally, we were not able to investigate associations with serum level of fatty acids or with other biomarkers of inflammation, which would have strengthened our results.
Strengths of our study included the use of a detailed repeated dietary records and test of the robustness of the results in sensitivity analysis.
In conclusion, our results supported inverse associations between both n-3 and n-6 PUFA intakes and elevated plasma CRP concentrations, and that vitamin E intakes should be carefully considered when investigating the effect of PUFA intakes on health outcomes.
